SpyGlass Pharma Reports Q1 Results

SpyGlass Pharma Reports Q1 Results
SpyGlass Pharma posted a GAAP loss per share of $0.69 in the first quarter. The company maintains $251 million in cash, which is sufficient to fund operations through 2028 without requiring additional financing. The company's Phase 3 BIM-IOL clinical trial enrollment is progressing on schedule, with completion expected in 2027. This financial position provides SpyGlass with a clear runway to advance its pipeline while pursuing regulatory approval for its lead candidate.